Drugs / (5R)-5-hydroxytriptolide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04084444 | Dec 2019 → Jul 2022 | immune dysregulation, autoimmunity, and autoinflammation | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | (5R)-5-hydroxytriptolide | “Its derivative (5R)-5-hydroxytriptolide (LLDT-8) on CD4 T cell recovery was assessed.” PMID 37283977 ↗ Mar 2023 |
| Known as | LLDT-8 | “Its derivative (5R)-5-hydroxytriptolide (LLDT-8) on CD4 T cell recovery was assessed.” PMID 37283977 ↗ Mar 2023 |
| Route | Oral | “The patients were 1:1:1 assigned to receive oral LLDT-8 0.5 mg or 1 mg daily, or placebo combined with antiretroviral therapy for 48 weeks.” PMID 37283977 ↗ Mar 2023 |